Form 4: Day One Biopharmaceuticals Executive Adam Dubow Reports Stock Transactions

Adam Dubow, General Counsel of Day One Biopharmaceuticals, reports the acquisition and disposal of common stock and Restricted Stock Units (RSUs) to cover tax liabilities.

Summary

• On August 15 and 16, 2024, Adam Dubow, General Counsel of Day One Biopharmaceuticals, engaged in transactions involving the company's common stock and Restricted Stock Units (RSUs).
• Dubow acquired shares through the vesting of RSUs on August 15, 2024, totaling 2,962, 1,750, and 3,687 shares respectively.
• On August 16, 2024, Dubow disposed of 3,202 shares at a price of $13.9991 per share.
• The sale of shares was solely to cover the reporting person's tax liability related to the settlement of RSUs.
• Following these transactions, Dubow directly owns 26,928 shares of common stock and holds 90,353 RSUs.

Sentiment

Score: 5

Explanation: The document reflects routine executive stock transactions, indicating a neutral sentiment.

Positives

• The transactions reflect the standard vesting and tax-related sales of equity compensation, which is a normal part of executive compensation.

Future Outlook

The document does not contain any specific forward-looking statements about the company's future performance.

Industry Context

This filing is a routine disclosure related to executive compensation and stock ownership, common in the biopharmaceutical industry.

Comparison to Industry Standards

• Executive stock transactions are a standard practice in publicly traded companies, including those in the biopharmaceutical sector.
• Companies like Amgen, Gilead Sciences, and Biogen also regularly report similar Form 4 filings for their executives.
• The vesting schedules and tax-related sales are typical components of equity compensation packages.

Stakeholder Impact

• The transactions have a minimal direct impact on stakeholders, as they are related to executive compensation and tax obligations.

Key Dates